Instrument Inactif

Communiqués Catabasis Pharmaceuticals Inc Nasdaq

Actions

US14875P1075

Recherche biotechnologique et médicale

Communiqués

21/01	Astria Stockholders Vote to Approve Acquisition by BioCryst	BU
12/11	Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update	BU
06/11	Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart	BU
03/11	Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting	AQ
31/10/25	Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting	BU
17/10/25	Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS	BU
14/10/25	BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile	BU
14/10/25	BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile	AQ
09/10/25	Astria Therapeutics Initiates the Phase 3 ORBIT EXPANSE Long Term Trial of Navenibart in People with Hereditary Angioedema	AQ
09/10/25	Astria Therapeutics to Present at Upcoming CSACI 80th Anniversary Scientific Meeting	BU
08/10/25	Astria Therapeutics Initiates the Phase 3 ORBIT-EXPANSE Long-Term Trial of Navenibart in People with Hereditary Angioedema	BU
03/10/25	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635c4	AQ
03/10/25	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	AQ
03/10/25	Astria Therapeutics to Present at Upcoming 2025 HAEi Regional Conference EMEA	BU
03/10/25	Astria Therapeutics recrute actuellement des patients atteints d’angio-œdème héréditaire dans l’Union européenne pour l’essai de phase III ALPHA-ORBIT	BU
02/10/25	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
02/10/25	Astria Therapeutics Now Enrolling HAE Patients in the European Union for the Phase 3 ALPHA-ORBIT Trial	BU
17/09/25	Astria Therapeutics : Corporate Presentation	PU
17/09/25	Astria Therapeutics Announces Positive Initial Results from the Phase 1a Healthy Subject Trial of STAR-0310 at the European Academy of Dermatology and Venereology	BU
03/09/25	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
03/09/25	Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology & Venereology Congress 2025	BU
27/08/25	Astria Therapeutics to Present at Upcoming Cantor Global Healthcare Conference	BU
12/08/25	Astria Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update	BU
06/08/25	Astria Therapeutics Enters into Licensing Agreement with Kaken Pharmaceutical to Develop and Commercialize Navenibart for HAE in Japan	BU
04/08/25	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU